Sjögren’s syndrome does not go away. It is a chronic autoimmune disease with no known cure, and once the immune system begins damaging moisture-producing glands, that damage is generally permanent. However, the disease can fluctuate over time, with periods of lower activity that may feel like improvement, followed by flares where symptoms intensify.
Why the Damage Is Permanent
In Sjögren’s syndrome, the immune system mistakenly attacks the glands that produce tears and saliva. White blood cells infiltrate these glands, clustering around ducts and blood vessels, creating areas of chronic inflammation. Over time, this inflammation destroys the gland tissue itself. The cells that once produced moisture are replaced by immune cells and scar tissue that cannot do the same job.
The process is self-sustaining. Damage to the gland lining triggers more immune activity, which causes more damage, which triggers still more immune activity. Proteins involved in this cycle keep the gland cells in a state of stress, eventually pushing them toward cell death. Because the body cannot regenerate these specialized gland structures once they are destroyed, the dryness that results tends to be permanent. This is why treatment focuses on managing symptoms rather than reversing the disease.
Flares, Remission, and What They Mean
Like many autoimmune conditions, Sjögren’s syndrome moves through periods of higher and lower disease activity. During a flare, you might notice worse dryness, swollen salivary glands, increased fatigue, or joint pain. During quieter periods, symptoms can ease noticeably, sometimes enough to feel like the disease has gone away.
It hasn’t. Clinicians measure disease activity on a standardized scale, and while scores can drop significantly during calmer stretches, once gland architecture is damaged, complete disease remission is not considered achievable. The dryness symptoms, in particular, tend to remain stable or worsen rather than resolve, even when other aspects of the disease quiet down. A period of feeling better is a welcome break, not a sign that the condition has reversed.
Symptoms Beyond Dryness
Most people think of Sjögren’s as dry eyes and dry mouth, but the disease can reach well beyond those glands. Joint pain is extremely common, with up to 96% of patients reporting it at some point. About 17% develop actual joint inflammation. Lung involvement occurs in up to 20% of patients, and nerve problems, ranging from tingling and numbness to more significant dysfunction, affect roughly 4% to 16%.
There is also a well-documented link to a type of blood cancer called non-Hodgkin lymphoma. People with Sjögren’s syndrome face about a 4.3-fold higher risk compared to the general population, with roughly 3% to 10% of patients developing it over their lifetime. This is one of the reasons ongoing monitoring matters, even during periods when symptoms feel manageable.
When Sjögren’s Occurs Alongside Other Conditions
Sjögren’s syndrome sometimes develops on its own (primary) and sometimes appears alongside another autoimmune disease (secondary). The most common overlap conditions are rheumatoid arthritis, lupus, and autoimmune thyroid disease. About 20% of people with lupus also meet criteria for secondary Sjögren’s. When it occurs this way, the two diseases share genetic and environmental risk factors, and the dryness symptoms behave similarly to primary Sjögren’s. Treating the underlying condition may reduce some systemic inflammation, but the gland damage from Sjögren’s itself follows the same irreversible pattern.
How Symptoms Are Managed
Since the disease cannot be cured, treatment is built around reducing discomfort and preventing complications. For dryness, the first line is straightforward: artificial tears used several times a day, and saliva substitutes or frequent sips of water for dry mouth. When dryness is severe, prescription eye drops that reduce inflammation in the tear glands can help, and oral medications that stimulate whatever gland function remains can increase both tear and saliva production. These are taken three times daily and work by nudging the glands to secrete more fluid.
For joint pain, over-the-counter anti-inflammatory drugs like ibuprofen are often enough. When they are not, immune-suppressing medications can dial back the overactive immune response driving the inflammation. The mildest option is typically tried first, with stronger drugs reserved for cases where the disease is affecting major organs like the lungs, kidneys, or brain.
Fatigue and widespread pain, which overlap with fibromyalgia in some patients, are treated separately with medications that calm overactive nerve signaling or adjust brain chemicals involved in pain perception.
Daily Habits That Make a Difference
Because dryness is constant, small environmental and hygiene adjustments add up. Running a humidifier at night or during dry winter months helps. Avoiding heavily air-conditioned or heated rooms reduces moisture loss from eyes and mouth. Some common medications, particularly decongestants, can worsen dryness and are worth discussing with your doctor if you take them regularly.
Dental care deserves special attention. Saliva protects teeth from decay, so without enough of it, cavities develop faster than normal. Brushing after every meal, flossing daily, and using toothpaste or rinses designed for dry mouth all help protect your teeth. Fluoride rinses may be recommended. A white coating on the tongue or cracks at the corners of the mouth can signal a fungal infection, which is more common when the mouth stays dry, and is treatable with antifungal medication.
New Treatments in Development
While no existing treatment can reverse Sjögren’s, several newer therapies are moving through late-stage clinical trials. Some target specific antibodies circulating in the blood, reducing them to lower levels so they cause less gland damage. Others block the survival signals that keep the immune cells responsible for the attack alive and active. One of these, which targets two key survival signals for immune cells at once, has shown promising phase 3 trial results in patients with gland swelling and elevated antibody levels. None of these are available yet as standard treatments, but they represent a shift toward addressing the underlying immune dysfunction rather than just managing symptoms.